Mark Cobbold, SVP of IO Discovery and Cell Therapy Oncology at AstraZeneca, shared a post on LinkedIn:
“It’s been a busy year for our cell therapy and IO teams at AstraZeneca! A few moments truly stand out.
Our internal cell therapy summit was a powerful opportunity to unite teams and reaffirm our commitment to realizing the full curative potential of cell therapy for patients worldwide. This event set the tone for the progress we’ve since made across our growing cell therapy portfolio, now spanning oncology, immune-mediated diseases and rare conditions. Earlier this month it was hugely exciting to see data presented from our first cell therapy clinical trial in multiple myeloma, moving us closer to translating scientific discovery into potential cures.
In 2025, we welcomed EsoBiotec colleagues into AstraZeneca, adding in vivo capabilities that complement our existing platforms. I’m excited by the promise this technology holds for expanding access to cell therapies in the future. A huge amount of work goes into making these collaborations possible, and I was delighted to see these efforts recognized with two recent award wins to close out the year: Best Venture Capital Deal in Life Sciences at the Belgian M&A Awards, and the Innovation Award at this year’s Scrip. These wins are testament to the dedication of our teams and the power of collaboration to help deliver tomorrow’s breakthroughs for patients – congratulations to all involved!
At SITC25, we showcased preclinical data for a next-generation CD8-guided immunocytokine – a great opportunity for the team to engage with the IO community about how these innovative molecules could boost or extend the endogenous and synthetic anti-tumor immune response.
None of this would be possible without the commitment and talent of our teams. I’m truly grateful for everyone whose passion drives us toward our bold ambition: to eliminate cancer as a cause of death.
Wishing you all a joyful holiday season—I can’t wait to see what we achieve together in 2026!”
More posts featuring Mark Cobbold.
